Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Replicel Life Sciences Inc V.RP

Alternate Symbol(s):  REPCF

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.


TSXV:RP - Post by User

Post by RPINVESTOR1on Oct 21, 2024 7:39pm
110 Views
Post# 36275831

A FAIR DEAL

A FAIR DEAL1. 75% on Gross Asset Sales.

2. 50% on Gross Royalties.

3. 2 minority shareholders on Board of Private Company.

4. All volunteer Replicel Board of Directors. Each Director must hold a minimum of 100,000 shares in Replicel. At least 2 new members not chosen by the current Board.  

5. No conversion of options to shares in Replicel. The option recipients have not been able to excercise these options because their efforts have not improved the fortunes of the Company or the share price. Converting these options to shares and increasing the total share count at the expense of the long-suffering small shareholders is abusive and unacceptable.

6. All further Replicel expenses to be paid by the Private Company.

 
<< Previous
Bullboard Posts
Next >>